Biomarin Pharmaceutical (BSP:B1MR34) Days Sales Outstanding : 85.48 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Biomarin Pharmaceutical Days Sales Outstanding?

Biomarin Pharmaceutical's average Accounts Receivable for the three months ended in Dec. 2023 was R$2,966 Mil. Biomarin Pharmaceutical's Revenue for the three months ended in Dec. 2023 was R$3,166 Mil. Hence, Biomarin Pharmaceutical's Days Sales Outstanding for the three months ended in Dec. 2023 was 85.48.

The historical rank and industry rank for Biomarin Pharmaceutical's Days Sales Outstanding or its related term are showing as below:

BSP:B1MR34' s Days Sales Outstanding Range Over the Past 10 Years
Min: 62.13 Med: 73.3 Max: 86.77
Current: 86.77

During the past 13 years, Biomarin Pharmaceutical's highest Days Sales Outstanding was 86.77. The lowest was 62.13. And the median was 73.30.

BSP:B1MR34's Days Sales Outstanding is ranked worse than
58.31% of 890 companies
in the Biotechnology industry
Industry Median: 71.92 vs BSP:B1MR34: 86.77

Biomarin Pharmaceutical's Days Sales Outstanding increased from Dec. 2022 (74.76) to Dec. 2023 (85.48).

Biomarin Pharmaceutical Days Sales Outstanding Historical Data

The historical data trend for Biomarin Pharmaceutical's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Days Sales Outstanding Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

75.14

73.52

77.23

75.22

85.06

Biomarin Pharmaceutical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															74.76	81.28	95.95	92.00	85.48

Competitive Comparison of Biomarin Pharmaceutical's Days Sales Outstanding

For the Biotechnology subindustry, Biomarin Pharmaceutical's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomarin Pharmaceutical's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Days Sales Outstanding falls into.

Biomarin Pharmaceutical Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Biomarin Pharmaceutical's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (2419.787	+	3105.023)	/	2 )	/	11853.724	*	365
=	2762.405					/	11853.724	*	365
=	85.06

Biomarin Pharmaceutical's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (2827.396	+	3105.023)	/	2 )	/	3166.285	*	365 / 4
=	2966.2095					/	3166.285	*	365 / 4
=	85.48

Biomarin Pharmaceutical (BSP:B1MR34) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Biomarin Pharmaceutical Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical (BSP:B1MR34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (BSP:B1MR34) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

BMRN:USA 1BMRN:Italy BM8:Germany

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (BSP:B1MR34) Headlines

No Headlines